Next Article in Journal
Metaphedrone (3-Methylmethcathinone): Pharmacological, Clinical, and Toxicological Profile
Previous Article in Journal
Intravenous Vitamin C as an Add-on Therapy for the Treatment of Sepsis in an Intensive Care Unit: A Prospective Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 60
Issue 3
10.3390/medicina60030465
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Diagnostic Challenges in Inflammatory Choroidal Neovascularization

by
Izabella Karska-Basta
1,2,
Weronika Pociej-Marciak
1,2,
Katarzyna Żuber-Łaskawiec
1,2,
Anna Markiewicz
1,2,
Michał Chrząszcz
2,
Bożena Romanowska-Dixon
1,2 and
Agnieszka Kubicka-Trząska
1,2,*
1
Chair of Ophthalmology, Faculty of Medicine, Medical College, Jagiellonian University, Kopernika Str. 38, 31-501 Krakow, Poland
2
Clinic of Ophthalmology and Ocular Oncology, University Hospital, Kopernika Str. 38, 31-501 Krakow, Poland
*
Author to whom correspondence should be addressed.
Medicina 2024, 60(3), 465; https://doi.org/10.3390/medicina60030465
Submission received: 3 February 2024 / Revised: 24 February 2024 / Accepted: 8 March 2024 / Published: 12 March 2024
(This article belongs to the Section Ophthalmology)
Browse Figures
Versions Notes

Abstract

:
Inflammation plays a key role in the induction of choroidal neovascularization (CNV). Inflammatory choroidal neovascularization (iCNV) is a severe but uncommon complication of both infectious and non-infectious uveitides. It is hypothesized that its pathogenesis is similar to that of wet age-related macular degeneration (AMD), and involves hypoxia as well as the release of vascular endothelial growth factor, stromal cell-derived factor 1-alpha, and other mediators. Inflammatory CNV develops when inflammation or infection directly involves the retinal pigment epithelium (RPE)–Bruch’s membrane complex. Inflammation itself can compromise perfusion, generating a gradient of retinal–choroidal hypoxia that additionally promotes the formation of choroidal neovascularization in the course of uveitis. The development of choroidal neovascularization may be a complication, especially in conditions such as punctate inner choroidopathy, multifocal choroiditis, serpiginous choroiditis, and presumed ocular histoplasmosis syndrome. Although the majority of iCNV cases are well defined and appear as the “classic” type (type 2 lesion) on fluorescein angiography, the diagnosis of iCNV is challenging due to difficulties in differentiating between inflammatory choroiditis lesions and choroidal neovascularization. Modern multimodal imaging, particularly the recently introduced technology of optical coherence tomography (OCT) and OCT angiography (noninvasive and rapid imaging modalities), can reveal additional features that aid the diagnosis of iCNV. However, more studies are needed to establish their role in the diagnosis and evaluation of iCNV activity.

1. Introduction

Uveitis-related choroidal neovascularization (CNV), known as inflammatory CNV (iCNV), is an uncommon complication of uveitis. At the same time, it is one of the most severe causes of visual impairment in patients with uveitis [1,2,3]. Inflammatory CNV is the third cause of CNV following wet age-related macular degeneration (AMD) and pathological myopia [2,3]. Inflammatory CNV develops more frequently in patients with posterior uveitis (2.7%) and panuveitis (0.8%) as compared with those with anterior and intermediate uveitis (0.1%) [4]. CNV is a clinically important complication of both infectious and non-infectious uveitis and is found to be more frequent in some specific clinical entities. Its incidence in non-infectious posterior uveitis has been reported to reach 2% [5]. A higher incidence of CNV was reported in multifocal choroiditis, punctate inner choroidopathy, serpiginous choroidopathy, birdshot retinochoroidopathy, and Vogt–Koyanagi–Harada disease [6,7,8,9,10,11,12,13,14,15,16,17,18]. On the other hand, data on the incidence of iCNV secondary to infectious uveitis are scarce and are derived mainly from case series and case reports. The prevalence of iCNV, depending on the etiology of uveitis, is presented in Table 1.
According to Baxter et al. [4], the presence of epiretinal neovascularization is associated with an over three-fold higher risk of iCNV. Moreover, the risk of CNV was significantly greater in eyes with active inflammation vs. those with inactive inflammation. The presence of anterior chamber cells grade 2+, as defined by the Standardization of Uveitis Nomenclature Working Group, was shown to be associated with iCNV. However, increased vitreous cells and vitreous haze were not significantly associated with an altered risk of incident CNV in patients with uveitis [4]. A previous diagnosis of CNV in the contralateral eye was associated with a several-fold higher risk of CNV in the second eye. However, the eyes of patients with bilateral uveitis were less likely to develop CNV than the affected eyes of patients with unilateral uveitis [4].
The underlying pathophysiology of iCNV is likely similar to the pathophysiology of CNV in other conditions associated with CNV, such as age-related macular degeneration (AMD) or pathologic myopia. Inflammatory CNV may thus be considered not as a distinct form of CNV, but rather as associated with a set of circumstances that permit its development [1,2,3].
It was demonstrated that vascular endothelial growth factor (VEGF) plays a key role in CNV development [2,3]. Moreover, CNV has an extravascular component consisting of fibroblasts and leukocytes that express C-X-C motif chemokine receptor 4 (CXCR4). Retinal pigment epithelial (RPE) cells showed an increased production of tumor necrosis factor as well as interleukins IL-1, IL-2, IL-6, and IL-10, accounting for the inflammatory component of CNV [47,48]. Also, other mediators are involved in CNV development, such as nitric oxide, angiostatin, endostatin, C-C chemokine receptor type 3 (CCR3), and pigment epithelium-derived growth factor (PEDF), contrasting the neovascularization [49].
Recently, D’Ambrosio et al. [8], based on the immunohistochemical staining grading of three structures of CNV, namely, the RPE, vascular network, and fibroblasts for SDF1, CXCR4, and VEGF receptor 2, revealed differences in the CXCR4 staining of the vascular meshwork of iCNV as compared with AMD-related CNV, suggesting that capillaries have a different role in membrane development [8]. However, because of a low P value for the CXCR4 staining of the vascular meshwork of uveitis-related CNV versus AMD-related CNV, the authors concluded that further studies on this distinctive aspect are necessary [8].
There are two pathophysiological mechanisms by which uveitis can promote the development of iCNV [2,47]. The first one is associated with inflammation-mediated damage of the RPE-Bruch’s membrane complex, which disrupts the outer blood-retinal barrier and permits neovascular upgrowth from the choroid. The damage can be induced by an angiogenic stimulus mediated by local inflammation, or it can result from a combination of both [2]. The imbalance between the inhibitory and stimulatory actions of the soluble mediators produced by the RPE is supposed to be the trigger of neoangiogenesis. Activated inflammatory cells secrete enzymes that damage cells and cause degradation in the Bruch’s membrane. Proangiogenic cytokines released by these inflammatory cells may promote CNV growth through breaks in the membrane and into the sub-RPE space, potentially leading to edema, exudation, hemorrhages, and fibrosis, resulting in profound central vision loss [1,2]. Thus, a higher risk of damage to the RPE–Bruch’s membrane complex related to adjacent chorioretinal inflammation may explain the higher incidence of iCNV in patients with panuveitis and posterior uveitis [50]. It is noteworthy that the RPE is often intact in individuals with iCNV, and a majority of iCNVs are type 2 lesions (“classic” type CNVs) with abnormal growth of the vasculature into the outer retinal space [2,8]. The proposed mechanism of iCNV development is thus the focal breach of the RPE due to infection or inflammation leading to the growth and entry of new vessels into the outer retinal space [50]. The second theory explains that retinal and choroidal inflammation directly compromises perfusion, generating a gradient of retinal–choroidal hypoxia that promotes the formation of choroidal neovascularization [2]. It should also be noted that, in some cases, “idiopathic” choroidal neovascularization may herald the subsequent development of posterior uveitis [51].
Inflammatory CNV is typically diagnosed when a patient with uveitis reports a sudden deterioration of vision and/or metamorphopsias [2,3,4,52]. In advanced cases of iCNV, a central scotoma may be present. Some active extrafoveal lesions can be asymptomatic and may be missed initially due to the presence of associated features such as inflammatory lesions, scars, and pigmentation, as well as intra- or subretinal fluid accumulation [1,2,3,8]. In such cases, iCNV may be detected in imaging studies [1,6,52,53].
Inflammatory CNV lesions typically grow close to the edge of a postinflammatory atrophic chorioretinal scar, although iCNV can rarely be synchronous with an active disease [52,53]. Inflammatory CNVs can be subfoveal, extrafoveal, or juxtafoveal, and are highly focal [8]. These can be associated with intra- or subretinal hemorrhages and exudations. Inactive iCNV can result in a subretinal yellow-white scar, which may be associated with fibrosis and pigmentation. The presence of intra- or subretinal fluid with iCNV, as well as serous retinal detachment, may also represent signs of inflammation, leading to a misdiagnosis during a basic ophthalmological examination [1,2,3,4,8].
Thus, in patients with posterior uveitis, the identification of iCNV is challenging due to related abnormalities, including choroiditis, chorioretinal scarring, and inflammatory lesions [52,53]. Difficulties in a differential diagnosis of iCNV and active inflammatory lesions arise from the characteristic presence of intraretinal or subretinal fluid as well as serous retinal detachment in both [1,8,52]. An accurate characterization of inflammatory lesions is important for the diagnosis of an underlying pathology and the implementation of adequate treatment.
The aim of this paper was to discuss current multimodal imaging tools for the diagnosis of iCNV, with an emphasis on technological advances and future perspectives.

2. Imaging Tools for the Detection of iCNV

2.1. Fluorescein Angiography

Fluorescein angiography (FA) has been widely employed in the diagnosis of CNV secondary to various ocular pathologies. Since iCNV is often a classic type of neovascular membrane (type 2), it can be visualized by FA. CNV lesions are present on FA as early iso- or hyperfluorescence with late leakage [54]. Similarly, active inflammatory lesions show features of early isofluorescence (although mostly hypofluorescence) and late leakage, while inactive atrophic lesions are characterized by early hypo- or isofluorescence with late staining (suggesting an RPE window defect) without leakage [4,55,56] (Figure 1 and Figure 2). These highly similar FA features of iCNV and inflammatory lesions pose a diagnostic challenge. In conditions such as multifocal choroiditis, serpiginous choroiditis, or Vogt–Koyanagi–Harada disease, which present with scarring and pigmentation due to extensive retinal involvement, the detection of hyperfluorescence associated with CNV may be particularly difficult [52,53,57]. Thus, FA alone may be insufficient to identify iCNV lesions and initiate appropriate therapy. Therefore, a multimodal approach with additional tests is recommended.

2.2. Indocyanine Green Angiography

One of the imaging techniques for the visualization of the choroid is indocyanine green angiography (ICGA), which allows a better visualization of the choroid compared with FA [58]. ICGA plays an important role in assessing pathologies involving the choroidal vasculature and choriocapillaris in chorioretinal inflammatory diseases. It is helpful in differentiating between iCNV and inflammatory lesions [59,60]. ICGA allows us to tell the difference between a recurrent inflammatory focus and iCNV: the former appears as an early hypofluorescent lesion, whereas the latter has been a hyperfluorescent lesion since early angiographic frames [58,59]. ICGA is also mandatory in the case of CNV associated with choriocapillaritis, such as multifocal choroiditis (MFC), where it shows the extent of occult choriocapillaris nonperfusion and hence the risk for CNV development [60,61]. CNV secondary to MFC is more frequent in inflamed areas; however, this may originate from an old chorioretinal scar as well. Low-grade chronic inflammation can be at the core of this process, and ICGA frequently shows areas of non-perfusion indicating ischemia, which may be the trigger of angiogenesis. In such cases, ICGA is essential in the evaluation of the choroidal status. Importantly, ICGA was shown to outperform FA in detecting occult CNV lesions [54]. While iCNV is typically a classic lesion that can be easily visualized by FA, ICGA has been recently reported to be more accurate in assessing the size of neovascular lesions, especially in patients with idiopathic CNV, which shares several clinical features with iCNV [62]. Thus, ICG helps identify both iCNV and inflammatory choroidal alterations in patients with uveitis, allowing clinical differentiation between these lesions and a more comprehensive evaluation of the disease [60] (Figure 3 and Figure 4).

2.3. Optical Coherence Tomography

Optical coherence tomography (OCT) is a noninvasive and highly repeatable imaging technique that has revolutionized the management of retinal and choroidal diseases. By providing the quasi-histological sections of the ocular structure, it allows clinicians to identify ocular pathologies and assess response to treatment [63]. Moreover, the enhanced depth imaging modality of OCT can be used to evaluate choroidal thickness and structural modifications, which is particularly valuable in the treatment of uveitis [63].
Inflammatory CNV usually develops between the RPE and neurosensory retina, demonstrating similar features on OCT imaging as classic (type 2) CNV [58]. In both cases, the lesions appear as hyperreflective structures located in front of a disrupted RPE, with solid tissue in the subretinal space [1,64,65,66]. However, there is a single OCT feature that can help distinguish between iCNV and other classic CNVs. This is the so-called “pitchfork sign”, characterized by finger-like hyperreflective lesions extending from the CNV into the outer retinal layers, and it allows us to differentiate iCNV from other causes of CNV [1,53,67,68] (Figure 5). The inflammatory conditions associated with this sign include idiopathic multifocal choroiditis/punctate inner choroidopathy (MFC/PIC), intraocular tuberculosis, and acute syphilitic posterior placoid chorioretinitis [1,53,67,68]. Rajabian et al. and Berensztejn et al. reported “pitchfork signs” in patients with choroidal osteoma. The authors proposed that inflammation is the most important stimulus for the development of CNV in these cases [69,70]. However, recently, Falavrajani et al. [71] have described the “pitchfork sign” in five eyes with type 2 CNV and without any sign of ocular inflammation. They speculated that traction of the type 2 CNV complex on the outer retinal layers and consequent dragging of the layers or Müller cell activation could explain the presence of the “pitchfork sign” [71].
It was reported that the OCT features of CNV activity such as retinal thickening, subretinal and intraretinal fluid, intraretinal hyperreflective flecks, and undefined boundaries of subretinal material predicted the presence of FA leakage [1,66] (Figure 6b,g). Thus, it was concluded that OCT can be used for monitoring disease progression and response to treatment [68,72].
Moreover, central retinal thickness evaluated by OCT is often used as an objective measure of iCNV activity [73,74,75]. Recently, Giuffrè et al. [76] demonstrated increased choroidal thickness under iCNV that decreases after therapy: the so-called “sponge sign” (Figure 7). The authors investigate choroidal thickness changes related to the clinical activity of inflammatory choroidal neovascularization in punctate inner choroidopathy/multifocal choroiditis as compared to myopic choroidal neovascularization. They found that choroidal thickness beneath inflammatory choroidal neovascularization significantly increased at baseline and decreased after therapy, reaching preclinical values. Conversely, no significant choroidal thickness changes were disclosed in myopic choroidal neovascularization eyes, under any location. Thus, OCT-based choroidal thickness evaluation may represent an additional useful tool to monitor inflammatory choroidal neovascularization activity. Moreover, choroidal thickness under CNV could be used to discriminate the origin of the choroidal neovascular membrane in doubtful cases (either inflammatory or myopic) and to guide therapeutic management [76].
OCT images can also help differentiate between iCNV lesions and non-neovascular alterations at the RPE level that are characteristic of several types of uveitis. For example, acute inflammatory foci in multifocal choroiditis show a deeper penetration of the OCT signal, a feature that is usually not seen in iCNV [56,65]. However, when distinguishing CNV lesions from iCNV, the use of OCT alone may be limited as these lesions display similar features of outer retinal or RPE hyperreflectivity, intraretinal edema, sub-RPE fluid, and exudation in conditions with the involvement of the RPE or choriocapillaris (e.g., multifocal choroiditis and punctate inner choroidopathy) [1,74,75,77,78]. In such cases, the characteristics of the lesions can be determined by a combination of FA, ICGA, and OCT angiography (OCTA).

2.4. Optical Coherence Tomography Angiography

The usefulness of OCTA as a noninvasive technique for the detection of iCNV has been reported by several investigators. Cheng et al. [79] assessed the ability of OCTA to detect iCNV and differentiate it from inflammatory lesions as compared with conventional FA in 26 patients with multifocal choroiditis. The authors concluded that OCTA outperformed FA in differentiating CNV from inflammatory lesions, as the latter do not show any blood flow signals. It also permitted the visualization of the detailed vascular structure of CNV. Therefore, it could be used as an alternative option for CNV identification and to guide therapeutic decision making [77]. Similarly, in a recent retrospective study of 14 patients, Zahid et al. [80] used OCTA to evaluate neovascular flow signals in macular chorioretinal lesions occurring in idiopathic multifocal choroiditis. They concluded that OCTA may be a useful tool for understanding the pathophysiology of the disease and monitoring its course. The utility of OCTA for the noninvasive diagnosis of iCNV and its subsequent follow-up was also confirmed by Yee et al. [81]. Finally, in a recent study, Aggarwal et al. [82] investigated the OCTA features of tuberculosis-associated choroiditis in comparison with conventional imaging modalities, including FA, ICGA, and OCTA. This was the first study to demonstrate that OCTA can identify type 1 neovascular networks. The research led to the conclusion that OCTA is indispensable to exclude neovascular networks when FA, ICGA, and OCT results are inconclusive [81] (Figure 6c–h, Figure 8 and Figure 9).
In patients with posterior uveitis, the identification of iCNV is challenging due to related abnormalities, including associated pathologies such as choroiditis, chorioretinal lesions, and choroidal scarring [1,82,83]. In such cases, OCTA allows noninvasive diagnostic imaging of iCNV and differentiation from inflammatory pathologies [1,82,83].
While the above studies prove the role of OCTA in the diagnosis and follow-up of patients with iCNV, larger prospective studies are needed to determine its advantages over conventional imaging.

2.5. Near-Infrared Autofluorescence Imaging

Fundus autofluorescence (FAF) is a valuable imaging tool for multiple anatomical and physiological alterations in the ocular tissue [84]. Essentially, FAF is a map of lipofuscin distribution, which is the autofluorescent pigment of the eye naturally found in the RPE–photoreceptor complex [85]. It was reported that iCNV lesions may show a different pattern on FAF imaging than active inflammatory foci [1,84,85]. In FAF, normal autofluorescence may occur in active iCNV with preserved neurosensory retina [1,83,84,85,86]. Prolonged active CNV tends to present hyperautofluorescence, while hypoautofluorescent areas correlate with photoreceptor and RPE loss [1,83,86] (Figure 1a and Figure 7b). Active inflammatory foci may show an increased autofluorescence signal [84,85] (Figure 3a). Therefore, the technique may be used for differentiating between inflammatory and CNV lesions.

3. Conclusions

The detection of inflammatory CNV remains a challenge due to the presence of choroiditis lesions, scarring, and pigmentation that make it difficult to visualize CNV lesions. Available case reports and case series point to the benefits of using OCTA in combination with conventional imaging modalities such as FA, OCT, and ICGA. This multimodal approach may improve the detection and follow-up of iCNV lesions. OCTA is also an important addition to FA and ICGA in terms of providing important information on retinochoroidal abnormalities associated with uveitis, such as the severity of inflammation or the presence of any vascular changes and focal lesions. It may offer advantages over traditional modalities in the detection of neovascular flow in uveitis, but it should be used as an additional tool rather than a replacement for the existing ones. Also, FAF requires further research to reveal whether this imaging modality can be used to differentiate between iCNV and inflammatory lesions and between AMD-related CNV and CNV related to inflammatory disease.

Author Contributions

Conceptualization, A.K.-T.; methodology, A.K.-T., I.K.-B. and W.P.-M.; software, K.Ż.-Ł., A.M. and M.C.; validation, A.K.-T. and B.R.-D.; formal analysis, A.K.-T., I.K.-B. and B.R.-D.; investigation, A.K.-T., I.K.-B. and W.P.-M.; resources, B.R.-D. and A.M.; data curation, K.Ż.-Ł., A.M., M.C. and W.P.-M.; writing—original draft preparation, A.K.-T., I.K.-B. and A.M.; writing—review and editing, A.K.-T., I.K.-B. and B.R.-D.; visualization, W.P.-M., M.C. and K.Ż.-Ł.; supervision, A.K.-T. and B.R.-D.; project administration, I.K.-B. and A.K.-T. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

The patients signed an institutional informed consent for the use of medical records and the publication of this information for research purposes.

Data Availability Statement

Data supporting the findings of this study are available upon request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Agarwal, A.; Invernizzi, A.; Singh, R.B.; Foulsham, W.; Aggarwal, K.; Handa, S.; Agrawal, R.; Pavesio, C.; Gupta, V. An update on inflammatory choroidal neovascularization: Epidemiology, multimodal imaging, and management. J. Ophthalmic Inflamm. Infect. 2018, 8, 13. [Google Scholar] [CrossRef]
  2. Dhingra, N.; Kelly, S.; Majid, M.A.; Bailey, C.B.; Dick, A.D. Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment. Indian. J. Ophthalmol. 2010, 58, 3–10. [Google Scholar] [CrossRef] [PubMed]
  3. Neri, P.; Lettieri, M.; Fortuna, C.; Manoni, M.; Giovannini, A. Inflammatory choroidal neovascularization. Middle East. Afr. J. Ophthalmol. 2009, 16, 245–251. [Google Scholar] [CrossRef] [PubMed]
  4. Baxter, S.L.; Pistilli, M.; Pujari, S.S.; Liesegang, T.L.; Suhler, E.B.; Thorne, J.E.; Foster, C.S.; Jabs, D.A.; Levy-Clarke, G.A.; Nussenblatt, R.B.; et al. Risk of choroidal neovascularization among the uveitides. Am. J. Ophthalmol. 2013, 156, 468–477. [Google Scholar] [CrossRef] [PubMed]
  5. Dreyer, R.F.; Gass, D.J. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch. Ophthalmol. 1984, 102, 1776–1784. [Google Scholar] [CrossRef] [PubMed]
  6. Morgan, C.M.; Schatz, H. Recurrent Multifocal Choroiditis. Ophthalmology 1986, 93, 1138–1147. [Google Scholar] [CrossRef] [PubMed]
  7. Brown, J., Jr.; Folk, J.C.; Reddy, C.V.; Kimura, A.E. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996, 103, 1100–1105. [Google Scholar] [CrossRef] [PubMed]
  8. Ahnood, D.; Madhusudhan, S.; Tsaloumas, M.D.; Waheed, N.K.; Keane, P.A.; Denniston, A.K. Punctate inner choroidopathy: A review. Surv. Ophthalmol. 2017, 62, 113–126. [Google Scholar] [CrossRef] [PubMed]
  9. Kuo, I.C.; Cunningham, E.T., Jr. Ocular neovascularization in patients with uveitis. Int. Ophthalmol. Clin. 2000, 40, 111–126. [Google Scholar] [CrossRef]
  10. Saatci, A.O.; Ayhan, Z.; Engin Durmaz, C.; Takes, O. Simultaneous Single Dexamethasone Implant and Ranibizumab Injection in a Case with Active Serpiginous Choroiditis and Choroidal Neovascular Membrane. Case Rep. Ophthalmol. 2015, 6, 408–414. [Google Scholar] [CrossRef]
  11. Kępka, M.; Brydak-Godowska, J.; Ciszewska, J.; Turczyńska, M.; Ciszek, M.; Kęcik, D. Clinical features, diagnosis and management of serpiginuos choroiditis. Ophthalmol. J. 2022, 7, 127–135. [Google Scholar] [CrossRef]
  12. Rao, N.A.; Gupta, A.; Dustin, L.; Chee, S.P.; Okada, A.A.; Khairallah, M.; Bodaghi, B.; Lehoang, P.; Accorinti, M.; Mochizuki, M.; et al. Frequency of distinguishing clinical features in Vogt Koyanagi-Harada disease. Ophthalmology 2010, 117, 591–599. [Google Scholar] [CrossRef]
  13. Brucker, A.J.; Deglin, E.A.; Bene, C.; Hoffman, M.E. Subretinal Choroidal Neovascularization in Birdshot Retinochoroidopathy. Am. J. Ophthalmol. 1985, 99, 40–44. [Google Scholar] [CrossRef] [PubMed]
  14. Mehta, S.; Hariharan, L.; Ho, A.C.; Kempen, J.H. Peripapillary choroidal neovascularization in pars planitis. J. Ophthalmic Inflamm. Infect. 2013, 3, 13. [Google Scholar] [CrossRef]
  15. Nageeb, M.R. Intermediate Uveitis Complicated by Peripapillary Choroidal Neovascularization. Cureus 2022, 14, e31040. [Google Scholar] [CrossRef] [PubMed]
  16. Inagaki, M.; Harada, T.; Kiribuchi, T.; Ohashi, T.; Majima, J. Subfoveal choroidal neovascularization in uveitis. Ophthalmologica 1996, 210, 229–233. [Google Scholar] [CrossRef] [PubMed]
  17. Pagliarini, S.; Piguet, B.; Ffytche, T.J.; Bird, A.C. Foveal involvement and lack of visual recovery in APMPPE associated with uncommon features. Eye 1995, 9, 42–47. [Google Scholar] [CrossRef]
  18. Bowie, E.M.; Sletten, K.R.; Kayser, D.L.; Folk, J.C.; James, C. Acute Posterior Multifocal Placoid Pigment Epitheliopathy And Choroidal Neovascularization. Retina 2005, 25, 362–364. [Google Scholar] [CrossRef]
  19. Saatci, A.O.; Ayhan, Z.; Ipek, S.C.; Soylev Bajin, M. Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia. Turk. J. Ophthalmol. 2018, 48, 209–211. [Google Scholar] [CrossRef]
  20. Rouvas, A.A.; Ladas, I.D.; Papakostas, T.D.; Moschos, M.M.; Vergados, I. Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to multiple evanescent white dot syndrome. Eur. J. Ophthalmol. 2007, 17, 996–999. [Google Scholar] [CrossRef]
  21. Burova, M.; Stepanov, A.; Almesmary, B.; Jiraskova, N. Choroidal neovascularization in a patient after resolution of multiple evanescent white dot syndrome: A case report. Clin. Case Rep. 2022, 10, e05802. [Google Scholar] [CrossRef]
  22. Liu, T.Y.A.; Zhang, A.Y.; Wenick, A. Evolution of Choroidal Neovascularization due to Presumed Ocular Histoplasmosis Syndrome on Multimodal Imaging including Optical Coherence Tomography Angiography. Case Rep. Ophthalmol. Med. 2018, 2018, 4098419. [Google Scholar] [CrossRef]
  23. Hu, J.; Hoang, Q.V.; Chau, F.Y.; Blair, M.P.; Lim, J.I. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis. Retin. Cases Brief. Rep. 2014, 8, 24–29. [Google Scholar] [CrossRef]
  24. Nielsen, J.S.; Fick, T.A.; Saggau, D.D.; Barnes, C.H. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2012, 32, 468–472. [Google Scholar] [CrossRef] [PubMed]
  25. Walia, H.S.; Shah, G.K.; Blinder, K.J. Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection. Can. J. Ophthalmol. 2016, 51, 91–96. [Google Scholar] [CrossRef]
  26. Zonnevylle, K.E.; Stanescu-Segall, D. Intravitreal Bevacizumab for Treatment of Bilateral Candida Chorioretinitis Complicated with Choroidal Neovascularization. Ocul. Immunol. Inflamm. 2020, 28, 39–42. [Google Scholar] [CrossRef] [PubMed]
  27. Jampol, L.M.; Sung, J.; Walker, J.D.; Folk, J.C.; Townsend-Pico, W.A.; Lowder, C.Y.; Dodds, E.M.; Westrich, D.; Terry, J. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am. J. Ophthalmol. 1996, 121, 643–649. [Google Scholar] [CrossRef] [PubMed]
  28. Makragiannis, G.; Vahdani, K.; Carreño, E.; Lee, R.W.J.; Dick, A.D.; Ross, A.H. Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis. Int. Ophthalmol. 2018, 38, 781–785. [Google Scholar] [CrossRef] [PubMed]
  29. Fine, S.L.; Owens, S.L.; Haller, J.A.; Knox, D.L.; Patz, A. Choroidal neovascularization as a late complication of ocular toxoplasmosis. Am. J. Ophthalmol. 1981, 91, 318–322. [Google Scholar] [CrossRef] [PubMed]
  30. Willerson, D.; Aaberg, T.M.; Reeser, F.; Meredith, T.A. Unusual ocular presentation of acute toxoplasmosis. Br. J. Ophthalmol. 1977, 61, 693–698. [Google Scholar] [CrossRef] [PubMed]
  31. Benevento, J.D.; Jager, R.D.; Noble, A.G.; Latkany, P.; Mieler, W.F.; Sautter, M.; Meyers, S.; Mets, M.; Grassi, M.A.; Rabiah, P.; et al. Toxoplasmosis Study Group. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch. Ophthalmol. 2008, 126, 1152–1156. [Google Scholar] [CrossRef] [PubMed]
  32. Sienicka, P. Eye toxoplasmosis complicated by choroidal neovascularization effectively treated with the anti-vascular endothelial growth factor aflibercept. Klin. Ocz. 2022, 124, 114–119. [Google Scholar] [CrossRef]
  33. Lampariello, D.A.; Primo, S.A. Ocular toxocariasis: A rare presentation of a posterior pole granuloma with an associated choroidal neovascular membrane. J. Am. Optom. Assoc. 1999, 70, 245–252. [Google Scholar] [PubMed]
  34. Lyall, D.; Hutchison, B.; Gaskell, A.; Varikkara, M. Intravitreal Ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye 2010, 24, 1730–1731. [Google Scholar] [CrossRef]
  35. Yoon, D.Y.; Woo, S.J. Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report. Ocular Immunol. Inflamm. 2018, 26, 639–641. [Google Scholar] [CrossRef] [PubMed]
  36. Chung, Y.M.; Yeh, T.S.; Sheu, S.J.; Liu, J.H. Macular subretinal neovascularization in choroidal tuberculosis. Ann. Ophthalmol. 1989, 21, 225–229. [Google Scholar] [PubMed]
  37. Lee Kim, E.; Rodger, D.C.; Rao, N.A. Choroidal neovascularization secondary to tuberculosis: Presentation and management. Am. J. Ophthalmol. Case Rep. 2017, 6, 124–129. [Google Scholar] [CrossRef]
  38. Zhang, Y.K.; Fu, H.Y.; Guan, Y.; Li, Y.J.; Bai, H.Z. Concurrent tuberculous chorioretinitis with choroidal neovascularization and tuberculous meningitis: A case report. BMC Ophthalmol. 2020, 20, 227. [Google Scholar] [CrossRef]
  39. Interlandi, E.; Pellegrini, F.; Pavesio, C.; De Luca, M.; De Marco, R.; Papayannis, A.; Mandarà, E.; Cuna, A.; Cirone, D.; Ciabattoni, C.; et al. Intraocular Tuberculosis: A Challenging Case Mimicking Wet Age-Related Macular Degeneration. Case Rep. Ophthalmol. 2021, 12, 519–524. [Google Scholar] [CrossRef]
  40. Deutman, A.F.; Grizzard, W.S. Rubella retinopathy and subretinal neovascularization. Am. J. Ophthalmol. 1978, 85, 82–87. [Google Scholar] [CrossRef]
  41. Parodi, M.B.; Romano, F.; Montagna, M.; Bandello, F. Large choroidal excavation in a patient with rubella retinopathy. Eur. J. Ophthalmol. 2018, 28, 251–252. [Google Scholar] [CrossRef] [PubMed]
  42. Dewan, L.; Hasan, N.; Aron, N.; Chawla, R.; Sundar, D. Rubella retinopathy with choroidal neovascular membrane in a 7-year-old. Indian J. Ophthalmol. 2020, 68, 1176–1177. [Google Scholar] [CrossRef] [PubMed]
  43. Hirano, K.; Tanikawa, A.; Miyake, Y. Neovascular maculopathy associated with rubella retinopathy. Jpn. J. Ophthalmol. 2000, 44, 697. [Google Scholar] [CrossRef] [PubMed]
  44. Khairallah, M.; Ben Yahia, S.; Attia, S.; Jelliti, B.; Zaouali, S.; Ladjimi, A. Severe ischemic maculopathy in a patient with West Nile virus infection. Ophthalmic Surg. Lasers Imaging 2006, 37, 240–242. [Google Scholar] [CrossRef] [PubMed]
  45. Seth, R.K.; Stoessel, K.M.; Adelman, R.A. Choroidal neovascularization associated with West Nile virus chorioretinitis. Semin. Ophthalmol. 2007, 22, 81–84. [Google Scholar] [CrossRef] [PubMed]
  46. Zito, R.; Micelli Ferrari, T.; Di Pilato, L.; Lorusso, M.; Ferretta, A.; Ferrari, L.M.; Accorinti, M. Clinical course of choroidal neovascular membrane in West Nile virus chorioretinitis: A case report. J. Med. Case Rep. 2021, 15, 206. [Google Scholar] [CrossRef] [PubMed]
  47. Campa, C.; Costagliola, C.; Incorvaia, C.; Sheridan, C.; Semeraro, F.; De Nadai, K.; Sebastiani, A.; Parmeggiani, F. Inflammatory mediators and angiogenic factors in choroidal neovascularization: Pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010, 2010, 546826. [Google Scholar] [CrossRef]
  48. D’Ambrosio, E.; Tortorella, P.; Iannetti, L. Management of uveitis-related choroidal neovascularization: From the pathogenesis to the therapy. J. Ophthalmol. 2014, 2014, 450428. [Google Scholar] [CrossRef]
  49. Cerquaglia, A.; Fardeau, C.; Cagini, C.; Fiore, T.; LeHoang, P. Inflammatory Choroidal Neovascularization: Beyond the Intravitreal Approach. Ocul. Immunol. Inflamm. 2018, 26, 1047–1052. [Google Scholar] [CrossRef]
  50. Sato, K.; Takeda, A.; Hasegawa, E.; Jo, Y.; Arima, M.; Oshima, Y.; Ryoji, Y.; Nakazawa, T.; Yuzawa, M.; Nakashizuka, H.; et al. Interleukin-6 plays a crucial role in the development of subretinal fibrosis in a mouse model. Immunol. Med. 2018, 41, 23–29. [Google Scholar] [CrossRef]
  51. Tatar, O.; Adam, A.; Shinoda, K.; Stalmans, P.; Eckardt, C.; Lüke, M.; Bartz-Schmidt, K.U.; Grisanti, S. Expression of VEGF and PEDF in Choroidal Neovascular Membranes Following Verteporfin Photodynamic Therapy. Am. J. Ophthalmol. 2006, 142, 95–104. [Google Scholar] [CrossRef] [PubMed]
  52. Cunningham, E.T., Jr.; Pichi, F.; Dolz-Marco, R.; Freund, K.B.; Zierhut, M. Inflammatory Choroidal Neovascularization. Ocul. Immunol. Inflamm. 2020, 28, 2–6. [Google Scholar] [CrossRef] [PubMed]
  53. Bou Ghanem, G.; Neri, P.; Dolz-Marco, R.; Albini, T.; Fawzi, A. Review for Diagnostics of the Year: Inflammatory Choroidal Neovascularization-Imaging Update. Ocul. Immunol. Inflamm. 2023, 31, 819–825. [Google Scholar] [CrossRef] [PubMed]
  54. Machida, S.; Fujiwara, T.; Murai, K.; Kubo, M.; Kurosaka, D. Idiopathic choroidal neovascularization as an early manifestation of inflammatory chorioretinal diseases. Retina 2008, 28, 703–710. [Google Scholar] [CrossRef]
  55. Bansal, R.; Bansal, P.; Gupta, A.; Gupta, V.; Dogra, M.R.; Singh, R.; Katoch, D. Diagnostic challenges in inflammatory choroidal neovascular membranes. Ocul. Immunol. Inflamm. 2017, 25, 554–562. [Google Scholar] [CrossRef]
  56. Atmaca, L.S.; Batioğlu, F.; Atmaca, P. Evaluation of choroidal neovascularization in age-related macular degeneration with fluorescein and indocyanine green videoangiography. Ophthalmologica 1996, 210, 148–151. [Google Scholar] [CrossRef]
  57. Kotsolis, A.I.; Killian, F.A.; Ladas, I.D.; Yannuzzi, L.A. Fluorescein angiography and optical coherence tomography concordance for choroidal neovascularisation in multifocal choroidtis. Br. J. Ophthalmol. 2010, 94, 1506–1508. [Google Scholar] [CrossRef]
  58. Spaide, R.F.; Goldberg, N.; Freund, K.B. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina 2013, 33, 1315–1324. [Google Scholar] [CrossRef]
  59. Perentes, Y.; Van Tran, T.; Sickenberg, M.; Herbort, C.P. Subretinal neovascular membranes complicating uveitis: Frequency, treatments, and visual outcome. Ocul. Immunol. Inflamm. 2005, 13, 219–224. [Google Scholar] [CrossRef]
  60. Bischoff, P.M.; Flower, R.W. Ten years’ experience with choroidal angiography using indocyanine green dye: A new routine examination or an epilogue? Doc. Ophthalmol. 1985, 60, 235–291. [Google Scholar] [CrossRef]
  61. Agrawal, R.V.; Biswas, J.; Gunasekaran, D. Indocyanine green angiography in posterior uveitis. Indian J. Ophthalmol. 2013, 61, 148–159. [Google Scholar] [CrossRef] [PubMed]
  62. Herbort, C.P. Fluorescein and indocyanine green angiography for uveitis. Middle East. Afr. J. Ophthalmol. 2009, 16, 168–187. [Google Scholar] [CrossRef] [PubMed]
  63. Sulzbacher, F.; Kiss, C.; Munk, M.; Deak, G.; Sacu, S.; Schmidt-Erfurth, U. Diagnostic evaluation of type 2 (classic) choroidal neovascularization: Optical coherence tomography, indocyanine green angiography, and fluorescein angiography. Am. J. Ophthalmol. 2011, 152, 799–806.e1. [Google Scholar] [CrossRef] [PubMed]
  64. Rush, R.B.; Rush, S.W. Evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy. J. Ophthalmol. 2015, 2015, 642624. [Google Scholar] [CrossRef] [PubMed]
  65. Mrejen, S.; Spaide, R.F. Optical coherence tomography: Imaging of the choroid and beyond. Surv. Ophthalmol. 2013, 58, 387–429. [Google Scholar] [CrossRef] [PubMed]
  66. Amer, R.; Priel, E.; Kramer, M. Spectral-domain optical coherence tomographic features of choroidal neovascular membranes in multifocal choroiditis and punctate inner choroidopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2015, 253, 949–957. [Google Scholar] [CrossRef]
  67. Hoang, Q.V.; Cunningham, E.T., Jr.; Sorenson, J.A.; Freund, K.B. The “pitchfork sign” a distinctive optical coherence tomography finding in inflammatory choroidal neovascularization. Retina 2013, 33, 1049–1055. [Google Scholar] [CrossRef] [PubMed]
  68. Christakopoulos, C.; Munch, I. The ‘pitchfork sign’ on optical coherence tomography in a case of acute syphilitic posterior placoid chorioretinitis. Acta Ophthalmol. 2019, 97, e942–e943. [Google Scholar] [CrossRef]
  69. Rajabian, F.; Arrigo, A.; Grazioli, A.; Sperti, A.; Bandello, F.; Battaglia Parodi, M. Focal choroidal excavation and pitchfork sign in choroidal neovascularization associated with choroidal osteoma. Eur. J. Ophthalmol. 2021, 31, NP67–NP70. [Google Scholar] [CrossRef]
  70. Berensztejn, P.; Brasil, O.F. Re: The ’pitchfork sign’ a distinctive optical coherence tomography finding in inflammatory choroidal neovascularization. Retina 2015, 35, e23–e24. [Google Scholar]
  71. Falavarjani, K.G.; Au, A.; Anvari, P.; Molaei, S.; Ghasemizadeh, S.; Verma, A.; Tsui, I.; Sadda, S.; Sarraf, D. En face OCT of Type 2 neovascularization: A reappraisal of the pitchfork sign. Ophthalmic Surg. Lasers Imaging Retin. 2019, 50, 719–725. [Google Scholar] [CrossRef]
  72. Roy, R.; Saurabh, K.; Bansal, A.; Kumar, A.; Majumdar, A.K.; Paul, S.S. Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor. Indian J. Ophthalmol. 2017, 65, 295–300. [Google Scholar] [CrossRef] [PubMed]
  73. Mansour, A.M.; Mackensen, F.; Arevalo, J.F.; Ziemssen, F.; Mahendradas, P.; Mehio-Sibai, A.; Hrisomalos, N.; Lai, T.Y.; Dodwell, D.; Chan, W.M.; et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am. J. Ophthalmol. 2008, 146, 410–416. [Google Scholar] [CrossRef] [PubMed]
  74. Karti, O.; Ipek, S.C.; Ates, Y.; Saatci, A.O. Inflammatory Choroidal Neovascular Membranes in Patients with Noninfectious Uveitis: The Place of Intravitreal Anti-VEGF Therapy. Med. Hypothesis Discov. Innov. Ophthalmol. 2020, 9, 118–126. [Google Scholar]
  75. Mansour, A.M.; Arevalo, J.F.; Ziemssen, F.; Mehio-Sibai, A.; Mackensen, F.; Adan, A.; Chan, W.-M.; Ness, T.; Banker, A.S.; Dodwell, D.; et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am. J. Ophthalmol. 2009, 148, 310–316.e2. [Google Scholar] [CrossRef] [PubMed]
  76. Giuffrè, C.; Marchese, A.; Fogliato, G.; Miserocchi, E.; Modorati, G.M.; Sacconi, R.; Cicinelli, M.V.; Miere, A.; Amoroso, F.; Capuano, V.; et al. The “Sponge sign”: A novel feature of inflammatory choroidal neovascularization. Eur. J. Ophthalmol. 2021, 31, 1240–1247. [Google Scholar] [CrossRef] [PubMed]
  77. Invernizzi, A.; Pichi, F.; Symes, R.; Zagora, S.; Agarwal, A.K.; Nguyen, P.; Erba, S.; Xhepa, A.; De Simone, L.; Cimino, L.; et al. Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti vascular endothelial growth factors: A comparison between two treatment regimens. Br. J. Ophthalmol. 2020, 104, 1052–1056. [Google Scholar] [CrossRef] [PubMed]
  78. Wu, K.; Zhang, X.; Su, Y.; Ji, Y.; Zuo, C.; Li, M.; Wen, F. Clinical characteristics of inflammatory choroidal neovascularization in a Chinese population. Ocul. Immunol. Inflamm. 2016, 24, 261–267. [Google Scholar] [CrossRef] [PubMed]
  79. Cheng, L.; Chen, X.; Weng, S.; Mao, L.; Gong, Y.; Yu, S.; Xu, X. Spectral-domain optical coherence tomography angiography findings in multifocal choroiditis with active lesions. Am. J. Ophthalmol. 2016, 169, 145–161. [Google Scholar] [CrossRef]
  80. Zahid, S.; Chen, K.C.; Jung, J.J.; Balaratnasingam, C.; Ghadiali, Q.; Sorenson, J.; Rofagha, S.; Freund, K.B.; Yannuzzi, L.A. Optical coherence tomography angiography of chorioretinal lesions due to idiopathic multifocal choroiditis. Retina 2017, 37, 1451–1463. [Google Scholar] [CrossRef]
  81. Yee, H.Y.; Keane, P.A.; Ho, S.L.; Agrawal, R. Optical coherence tomography angiography of choroidal neovascularization associated with tuberculous serpiginous-like choroiditis. Ocul. Immunol. Inflamm. 2016, 24, 699–701. [Google Scholar] [CrossRef] [PubMed]
  82. Aggarwal, K.; Agarwal, A.; Sharma, A.; Sharma, K.; Gupta, V. OCTA Study Group. Detection Of Type 1 Choroidal Neovascular Membranes Using Optical Coherence Tomography Angiography In Tubercular Posterior Uveitis. Retina 2019, 39, 1595–1606. [Google Scholar] [CrossRef] [PubMed]
  83. Astroz, P.; Miere, A.; Mrejen, S.; Sekfali, R.; Souied, E.H.; Jung, C.; Nghiem-Buffet, S.; Cohen, S.Y. Optical coherence tomography angiography to distinguish choroidal neovascularization from macular inflammatory lesionns in multifocal choroiditis. Retina 2018, 38, 299–309. [Google Scholar] [CrossRef] [PubMed]
  84. Theelen, T.; Berendschot, T.T.J.M.; Hoyng, C.B.; Boon, C.J.F.; Klevering, B.J. Near-infrared reflectance imaging of neovascular age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247, 1625–1633. [Google Scholar] [CrossRef]
  85. Toju, R.; Iida, T.; Sekiryu, T.; Saito, M.; Maruko, I.; Kano, M. Near-infrared autofluorescence in patients with idiopathic submacular choroidal neovascularization. Am. J. Ophthalmol. 2012, 153, 314–319. [Google Scholar] [CrossRef]
  86. Samy, A.; Lightman, S.; Ismetova, F.; Talat, L.; Tomkins-Netzer, O. Role of autofluorescence in inflammatory/infective diseases of the retina and choroid. J. Ophthalmol. 2014, 2014, 418193. [Google Scholar] [CrossRef]
Medicina 60 00465 g001
Figure 1. (a) Fundus autofluorescence image, showing hypoautofluorescence of inactive postinflammatory lesions (red arrows) and hyperautofluorescence of active inflammatory lesions (green asterix); irregular autofluorescence is present above the postinflammatory scar suspected for inflammatory choroidal neovascularization (yellow arrow); (b,c) fluorescein angiography images, showing early isofluorescence with late staining (d) of the lesions as a result of a retinal pigmented epithelium window defect; no evident features of inflammatory choroidal neovascularization are observed.
Figure 1. (a) Fundus autofluorescence image, showing hypoautofluorescence of inactive postinflammatory lesions (red arrows) and hyperautofluorescence of active inflammatory lesions (green asterix); irregular autofluorescence is present above the postinflammatory scar suspected for inflammatory choroidal neovascularization (yellow arrow); (b,c) fluorescein angiography images, showing early isofluorescence with late staining (d) of the lesions as a result of a retinal pigmented epithelium window defect; no evident features of inflammatory choroidal neovascularization are observed.
Medicina 60 00465 g001
Medicina 60 00465 g002
Figure 2. (a) Color picture of the fundus showing inactive inflammatory foci in the macula region with changes at the retinal pigmented epithelium level; (b,c) fluorescein angiography images demonstrate early isofluorescence with late staining (d) of the lesions as a result of a retinal pigmented epithelium window defect without features of inflammatory choroidal neovascularization (red arrows).
Figure 2. (a) Color picture of the fundus showing inactive inflammatory foci in the macula region with changes at the retinal pigmented epithelium level; (b,c) fluorescein angiography images demonstrate early isofluorescence with late staining (d) of the lesions as a result of a retinal pigmented epithelium window defect without features of inflammatory choroidal neovascularization (red arrows).
Medicina 60 00465 g002
Medicina 60 00465 g003
Figure 3. (a) Fundus autofluorescence image shows hypoautoflurescence of inactive postinflammatory lesion in macula (red arrow) with hyperautofluorescent area representing the active inflammatory focus at its lower margin (green arrow), at the upper border of the scar the area of irregular autofluorescence is present (yellow arrow); (b,c) early and middle frames of indocyanine green (ICG) angiograms reveal a visibility of the choroidal vessels in the area of the inactive postinflammatory focus and small hypocyanescent area at its lower border corresponding to active choroidal inflammation; (d) late ICG angiogram demonstrates homogeneous hypocyanescence of the postinflammatory lesion with evidence of late hypercyanescence at its upper margin (yellow circle). The patient was diagnosed with inflammatory choridal neovascularization.
Figure 3. (a) Fundus autofluorescence image shows hypoautoflurescence of inactive postinflammatory lesion in macula (red arrow) with hyperautofluorescent area representing the active inflammatory focus at its lower margin (green arrow), at the upper border of the scar the area of irregular autofluorescence is present (yellow arrow); (b,c) early and middle frames of indocyanine green (ICG) angiograms reveal a visibility of the choroidal vessels in the area of the inactive postinflammatory focus and small hypocyanescent area at its lower border corresponding to active choroidal inflammation; (d) late ICG angiogram demonstrates homogeneous hypocyanescence of the postinflammatory lesion with evidence of late hypercyanescence at its upper margin (yellow circle). The patient was diagnosed with inflammatory choridal neovascularization.
Medicina 60 00465 g003
Medicina 60 00465 g004
Figure 4. (a,e) Color pictures of the fundus presenting well-defined and partially pigmented chorioretinal scars at the sites of previous chorioretinal inflammation in the macula of both eyes; (b,f) fundus autofluorescence demonstrate hypoautofluorescent foci that correlate with photoreceptor and retinal pigment epithelium damage; (c,d,g,h) early and late frames of indocyanine green angiograms revealed the presence of homogenous hypocyanescent foci related to retinal pigment epithelium damage due to postinflammatory scarring; no features of inflammatory choroidal neovascularization are observed.
Figure 4. (a,e) Color pictures of the fundus presenting well-defined and partially pigmented chorioretinal scars at the sites of previous chorioretinal inflammation in the macula of both eyes; (b,f) fundus autofluorescence demonstrate hypoautofluorescent foci that correlate with photoreceptor and retinal pigment epithelium damage; (c,d,g,h) early and late frames of indocyanine green angiograms revealed the presence of homogenous hypocyanescent foci related to retinal pigment epithelium damage due to postinflammatory scarring; no features of inflammatory choroidal neovascularization are observed.
Medicina 60 00465 g004
Medicina 60 00465 g005
Figure 5. (a) Color picture of the right eye diagnosed for punctate inner choroidopathy; (b) optical coherence tomography scan demonstrates hyperreflective material above the retinal pigment epithelium with the presence of subretinal and intraretinal fluid corresponding to an active inflammatory choroidal neovascularization with multiple vertical finger-like projections extending anteriorly into the outer retina—the “pitchfork sign” (yellow arrows).
Figure 5. (a) Color picture of the right eye diagnosed for punctate inner choroidopathy; (b) optical coherence tomography scan demonstrates hyperreflective material above the retinal pigment epithelium with the presence of subretinal and intraretinal fluid corresponding to an active inflammatory choroidal neovascularization with multiple vertical finger-like projections extending anteriorly into the outer retina—the “pitchfork sign” (yellow arrows).
Medicina 60 00465 g005
Medicina 60 00465 g006
Figure 6. (a) Color picture of the fundus shows macular subretinal fibrosis; (b) optical coherence tomography scan revealed hyperreflective material under the retinal pigment epithelium (yellow arrow), subretinal fluid is present (red arrow); (c–f) optical coherence tomography angiography (OCTA): the scan of the superficial capillary plexus is undisrupted (c); the scan of the deep capillary plexus shows a capillary impairment (d); the scans of outer retinal layer and choriocapillaris demonstrate pathological vessels presenting inflammatory choroidal neovascularization (iCNV) (yellow circles); (g) OCTA scan B presents the blood-flow in outer retinal layer (black arrows); (h) OCTA vessel density map is complementary and shows the presence of pathological vessels corresponding to iCNV (yellow circle).
Figure 6. (a) Color picture of the fundus shows macular subretinal fibrosis; (b) optical coherence tomography scan revealed hyperreflective material under the retinal pigment epithelium (yellow arrow), subretinal fluid is present (red arrow); (c–f) optical coherence tomography angiography (OCTA): the scan of the superficial capillary plexus is undisrupted (c); the scan of the deep capillary plexus shows a capillary impairment (d); the scans of outer retinal layer and choriocapillaris demonstrate pathological vessels presenting inflammatory choroidal neovascularization (iCNV) (yellow circles); (g) OCTA scan B presents the blood-flow in outer retinal layer (black arrows); (h) OCTA vessel density map is complementary and shows the presence of pathological vessels corresponding to iCNV (yellow circle).
Medicina 60 00465 g006
Medicina 60 00465 g007
Figure 7. (a,c) Color pictures of the right eye diagnosed for punctate inner choroidopathy; (b,d) optical coherence tomography scans demonstrate choroidal thickness (CT) changes under inflammatory choroidal neovascularization before and after the treatment—the “sponge sign”. Before treatment, CT corresponded to 257 µm and then decreased to 202 µm after intravitreal bevacizumab injection.
Figure 7. (a,c) Color pictures of the right eye diagnosed for punctate inner choroidopathy; (b,d) optical coherence tomography scans demonstrate choroidal thickness (CT) changes under inflammatory choroidal neovascularization before and after the treatment—the “sponge sign”. Before treatment, CT corresponded to 257 µm and then decreased to 202 µm after intravitreal bevacizumab injection.
Medicina 60 00465 g007
Medicina 60 00465 g008
Figure 8. (a1,a2) Early and middle stages of indocyanine green angiography present hypocyanescent spots indicating active inflammatory lesions (red arrows); (a3) late stage shows hypercyanescent plaque (green circle); (b–e) optical coherence tomography angiography (OCTA): the scan of the superficial apillary plexus is undisrupted (b); the scan of the deep capillary plexus shows a small area of capillary impairment below the macula (c); the scans of the outer retinal layer and choriocapillaris demonstrated pathological vessels presenting inflammatory choroidal neovascularization (green circles) (d,e); (f) OCTA B scan shows the presence of a trace of subretinal fluid (yellow arrow), blood flow in the outer retinal layers (green arrow), and intraretinal fluid (pink arrow), indicating the presence of active inflammatory choroidal neovascularization; (g) OCTA vessel density map presents a net of pathological vessels (yellow circle).
Figure 8. (a1,a2) Early and middle stages of indocyanine green angiography present hypocyanescent spots indicating active inflammatory lesions (red arrows); (a3) late stage shows hypercyanescent plaque (green circle); (b–e) optical coherence tomography angiography (OCTA): the scan of the superficial apillary plexus is undisrupted (b); the scan of the deep capillary plexus shows a small area of capillary impairment below the macula (c); the scans of the outer retinal layer and choriocapillaris demonstrated pathological vessels presenting inflammatory choroidal neovascularization (green circles) (d,e); (f) OCTA B scan shows the presence of a trace of subretinal fluid (yellow arrow), blood flow in the outer retinal layers (green arrow), and intraretinal fluid (pink arrow), indicating the presence of active inflammatory choroidal neovascularization; (g) OCTA vessel density map presents a net of pathological vessels (yellow circle).
Medicina 60 00465 g008
Medicina 60 00465 g009
Figure 9. (a) Early frame of fluorescein angiography demonstrates the presence of isofluorescence of the inactive inflammatory lesion related to serpiginous choroidopathy; (b) Late frame of fluorescein angiography presents hyperfluorescent area of inactive postinflammatory lesion as a result of a “window defect” with irregular staining above it (yellow arrow); (c–f) Optical coherence tomography angiography demonstrated normal superficial and deep capillary plexi (c,d); the scans of outer retina and choriocapillary layers show the net of pathological vessels (e,f); (g) OCTA B scan shows the presence of subretinal mass with blood flow (black arrows); (h) OCTA vessel density map presents a net of pathological vessels (yellow circle); (i) Optical coherence tomography presents the hyperreflective subretinal lesion (yellow arrow) with subretinal fluid (red arow) and intraretinal fluid (blue arrow) showing the evidence of active inflammatory choroidal neovasularization.
Figure 9. (a) Early frame of fluorescein angiography demonstrates the presence of isofluorescence of the inactive inflammatory lesion related to serpiginous choroidopathy; (b) Late frame of fluorescein angiography presents hyperfluorescent area of inactive postinflammatory lesion as a result of a “window defect” with irregular staining above it (yellow arrow); (c–f) Optical coherence tomography angiography demonstrated normal superficial and deep capillary plexi (c,d); the scans of outer retina and choriocapillary layers show the net of pathological vessels (e,f); (g) OCTA B scan shows the presence of subretinal mass with blood flow (black arrows); (h) OCTA vessel density map presents a net of pathological vessels (yellow circle); (i) Optical coherence tomography presents the hyperreflective subretinal lesion (yellow arrow) with subretinal fluid (red arow) and intraretinal fluid (blue arrow) showing the evidence of active inflammatory choroidal neovasularization.
Medicina 60 00465 g009
Table 1. Prevalence of inflammatory choroidal neovascularization (iCNV) depending on the etiology of uveitis.
Table 1. Prevalence of inflammatory choroidal neovascularization (iCNV) depending on the etiology of uveitis.
Type of UveitisPrevalence of iCNV [References]
Non-infectious
Multifocal choroiditis32–50% [4,5,6,7]
Punctate inner choroidopathy17–40% [1,4,8,9]
Serpiginous choroidopathy10–25% [4,10,11]
Vogt–Koyanagi–Harada disease9–15% [4,7,9,12]
Birdshot chorioretinitis5% [4,13]
Intermediate uveitissingle cases reported [14,15]
Behçet diseasevery rare [4,16]
Acute posterior multifocal placoid pigment epitheliopathysingle cases reported [4,16,17,18]
Sympathetic ophthalmiasingle cases reported [16,19]
Sarcoidosissingle cases reported [4,9,16]
Multiple evanescent white dot syndromesingle cases reported [4,20,21]
Infectious
Histoplasmosis5–17.4% [4,9,16,22,23,24,25]
Candidiasisrare; prevalence unknown [26,27,28]
Toxoplasmosis0.3–19% [29,30,31,32]
Toxocariasissingle cases reported [33,34,35]
Tuberculosissingle cases reported [36,37,38,39]
Rubella retinopathysingle cases reported [40,41,42,43]
West Nile virussingle cases reported [44,45,46]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Karska-Basta, I.; Pociej-Marciak, W.; Żuber-Łaskawiec, K.; Markiewicz, A.; Chrząszcz, M.; Romanowska-Dixon, B.; Kubicka-Trząska, A. Diagnostic Challenges in Inflammatory Choroidal Neovascularization. Medicina 2024, 60, 465. https://doi.org/10.3390/medicina60030465

AMA Style

Karska-Basta I, Pociej-Marciak W, Żuber-Łaskawiec K, Markiewicz A, Chrząszcz M, Romanowska-Dixon B, Kubicka-Trząska A. Diagnostic Challenges in Inflammatory Choroidal Neovascularization. Medicina. 2024; 60(3):465. https://doi.org/10.3390/medicina60030465

Chicago/Turabian Style

Karska-Basta, Izabella, Weronika Pociej-Marciak, Katarzyna Żuber-Łaskawiec, Anna Markiewicz, Michał Chrząszcz, Bożena Romanowska-Dixon, and Agnieszka Kubicka-Trząska. 2024. "Diagnostic Challenges in Inflammatory Choroidal Neovascularization" Medicina 60, no. 3: 465. https://doi.org/10.3390/medicina60030465

Article Metrics

Back to TopTop